the effect of rituximab in ttp patient refractory to plasmexchange
Phase 2
- Conditions
- TTP..thrombotic thrombocytopenic purpura
- Registration Number
- IRCT2017012232125N1
- Lead Sponsor
- vice chancellor for research of esfahan university of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
exclusion:viral infection, malignancy,autoimmune disease,drug(cyclosporine,ticlopidine,..)
inclusion:criteria for ttp diagnosis
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PLT-LDH. Timepoint: daily check to recieve to goal of treatmeant. Method of measurement: laboratory.
- Secondary Outcome Measures
Name Time Method BUN CR. Timepoint: at first daily check then weekly and monthly. Method of measurement: laboratory.;Level of consciousness. Timepoint: at first daily check then weekly and monthly. Method of measurement: clinical examination.;Drug complication. Timepoint: at first daily check then weekly and monthly. Method of measurement: clinical examination- laboratory.